News

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Recent Press Releases

Aug 28, 2014

GW Pharmaceuticals to Present at Upcoming Investor Conferences

London, UK, 28 August 2014: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics

Aug 06, 2014

GW Pharmaceuticals plc Reports 2014 Third Quarter Financial Results

-Conference Call Today at 8:00 a.m. ET, 1:00 p.m. BST-

Jul 30, 2014

GW Pharmaceuticals to Report Q3 2014 Financial Results and Host Conference Call on 6 August, 2014

London, UK, 30 July 2014: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its propri

Jun 25, 2014

GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Totaling Approximately $169.8 Million on the NASDAQ Global Market

LONDON, UK, 25 June, 2014 -- GW Pharmaceuticals plc (Nasdaq: GWPH) (AIM: GWP) ("GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its p

Jun 18, 2014

GW Pharmaceuticals plc Announces Pricing of U.S. Public Offering of ADSs Totaling Approximately $148 Million on NASDAQ Global Market

London, UK, 18 June 2014: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its propri

Jun 17, 2014

GW Pharmaceuticals Announces Physician Reports of Epidiolex® Treatment Effect in Children and Young Adults with Treatment-Resistant Epilepsy from Physician-Led Expanded Access Treatment Program

- Data show promising signals of efficacy and safety -

Jun 17, 2014

GW Pharmaceuticals Announces Proposed Public Offering of ADSs

London, UK, 17 June 2014: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its propri

Jun 06, 2014

GW Pharmaceuticals Announces Epidiolex® Receives Fast Track Designation from FDA for the Treatment of Dravet Syndrome

London, UK; 6 June 2014: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics fro

Jun 03, 2014

GW announces agreement with New York State to investigate use of CBD to treat medication-resistant epilepsies in children

London, UK, 3 June 2014: GW Pharmaceuticals plc (NASDAQ: GWPH, AIM: GWP, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics fro

May 27, 2014

A State of Georgia initiative making it possible to treat children with epilepsy with cannabidiol is moving forward

Atlanta, Georgia, and London, UK 27 May 2014: A State of Georgia initiative making it possible to treat children with epilepsy with cannabidiol is moving forward.

Cookie Notification

Media Contact

Recent Press Releases

Pages

News

Cookie Notification

Search form

Media Contact

Recent Press Releases

Pages